Psychedelics such as psilocybin, lysergic acid diethylamide (LSD) and Ketamine have long been excluded from mental therapeutic treatments due to stigmatization and lack of understanding. In recent years however, researchers and scientists have begun to unearth new discoveries and research in relation to the effectiveness of these substances in the treatment of depression, anxiety, and other mental health challenges.
Recent randomized clinical trials have indicated that Psilocybin-assisted therapy (the naturally-occurring psychedelic compound found in mushrooms) were found to be efficacious in producing large, rapid, and sustained antidepressant effects in patients with major depressive disorder (Davis et al., 2020). Other studies have concluded that classical psychedelics like ayahuasca, psilocybin and lysergic acid diethylamide (LSD) are potential therapeutic options for patients whose symptoms are not effectively managed by conventional treatment (Muttoni et al., 2019).
In this Frayme hosted webinar, a panel of researchers and youth will speak to the use of these treatments from an evidence-based lens that includes the triangulation of lived experience, research and service provision.
------
Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78(5):481–489. doi:10.1001/jamapsychiatry.2020.3285
Muttoni, S., Ardissino, M., & John, C. (2019). Classical psychedelics for the treatment of depression and anxiety: A systematic review. Journal of Affective Disorders, 258, 11–24. https://doi.org/10.1016/j.jad.2019.07.076
Participants in this webinar will:
1. Hear an intro to research on the use of psychedelics in treatment of mental illness
2. Listen to the lived expertise of a youth who has used ketamine to treat depression
3. Learn about systemic barriers and enablers for the use of these substances
Time: Aug 5, 2021 12:00 PM in Eastern Time (US and Canada)
Comments (0)